Davy Research

Malin Corporation

A unique life sciences opportunity
Pharma and healthcare
Malin Corporation

DAVY VIEW

Since its IPO in 2015, Malin has made significant progress in executing its strategy. It has allocated €372.5m across 18 portfolio companies, offering investors diversification of development and commercial risk and a spread of product/device/service plays through the healthcare life cycle. An uplift in observable fair value since 2015 indicates business model progression and shareholder value creation. Further development and commercial milestones are expected in the coming 12-18 months, which should lead to an increase in the observable fair value. We reiterate our ‘Outperform’ call with a price target of €16.90.

Download full report with analyst certification and important disclosures
Download
Download full report with analyst certification and important disclosures
Download
  • RATINGS AND PRICE CORRECT AT TIME OF ISSUE


  • Malin Corporation

    Closing Price: 1135c

  • RATING 29/09/15

  • PREVIOUS RATING N/A

Analyst(S)

COMPANY DATA

JUMP TO